avelumab – Patient Worthy

Axitinib-Avelumab Combination Prompted Responses in Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Post author:Jessica Lynn
Post published:March 27, 2023
Post category:Adenoid Cystic Carcinoma

While the five-year survival rate for adenoid cystic carcinoma (ACC) is relatively high, this cancer has a high risk of recurrence. Therapeutic options are needed to manage this cancer and…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More